What's it like in the virology division?

Discussion in 'Bristol-Myers Squibb' started by anonymous, Jul 1, 2018 at 7:06 PM.

Tags: Add Tags
  1. #1 anonymous, Jul 1, 2018 at 7:06 PM
    anonymous

    anonymous Guest

    Interested in selling in the BMS HIV or HCV space. How is it over there?
     
    Quote

  2. #2 anonymous, Jul 2, 2018 at 9:15 AM
    anonymous

    anonymous Guest

    Over. Both divisions closed
     
    Quote
  3. #3 anonymous, Jul 2, 2018 at 5:41 PM
    anonymous

    anonymous Guest

    What ever happened to Cathy Johnson in Virology? (used to be in PC in Atlanta)
     
    Quote
  4. #4 anonymous, Jul 7, 2018 at 9:18 PM
    anonymous

    anonymous Guest

    Well, that blows.
     
    Quote
  5. #5 anonymous, Jul 12, 2018 at 11:39 AM
    anonymous

    anonymous Guest

    1Q2018 Yahoo finance

    "The performance of key drugs in the Virology unit continues to disappoint. Sales of Baraclude declined 20% to $225 million. The Reyataz and Sustiva franchises deteriorated 36% and 54% year over year to $124 million and $84 million, respectively. The Hepatitis franchise lost 98% of its year-ago quarter sales and contributed a mere $3 million to revenue."
     
    Quote
  6. #6 anonymous, Sep 5, 2018 at 1:58 AM
    anonymous

    anonymous Guest

     
    Quote
Reply to Thread